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Abstract 
Osteonecrosis of the jaw (ONJ) may appear following certain oral surgery procedures in patients treated with oral 
bisphosphonates (OB). Guidelines for the treatment of these patients were set out in the American Association 
of Oral and Maxillofacial Surgeons (AAOMS) Position Paper on Bisphosphonate-Related Osteonecrosis of The 
Jaws (Position Paper) and Approved by the Board of Trustees in September 2006. For the AAOMS the placement 
of implants in these patients is not contraindicated. In addition, the serum C-terminal telopeptide bone suppressor 
marker (CTX) test is available to determine the risk of ONJ. A case is presented of ONJ in a patient with 6 months 
of OB discontinuation (“drug holiday”) before dental implant placement (following the guidelines of the AAOMS) 
and with no risk of osteonecrosis according to the serum CTX value (340 pg/ml). The wound healed favorably with 
complete healing at 7 months. In this case, the serum CTX test must be questioned as to its predictive value of ONJ, 
and more reliable markers of this risk are needed.
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Introduction
Osteonecrosis of the jaw (ONJ) is defined as the appea-
rance of exposed bone in the maxillofacial region per-
sisting for more than 8 weeks in patients with current or 
previous treatment with a bisphosphonate and no history 
of radiation therapy to the jaws (American Association 
of Oral and Maxillofacial Surgeons (AOMS)) (1).
According to the recommendations of the American As-
sociation of Oral and Maxillofacial Surgeons (AAOMS) 
(1), patients treated with oral bisphosphonates (OB) can 
receive dental implants. Marx et al. (2) found 2 cases of 
ONJ after placement of dental implants in patients ta-
king OB for more than 3 years, without specifying whe-
ther the bisphosphonates were removed before surgery. 
In contrast, a review by Grant et al. (3), of 468 dental 
implants placed in 115 patients treated with OB, found 
no evidence of ONJ, only 2 implants failed, and success 
rates were comparable to patients not taking OB. Marx 
et al. (2) recommend the serum C- terminal telopeptide 
(CTX) blood test on an empty stomach, to assess the 
bone turnover/renewal suppression caused by OB, and 
so evaluate the risk of ONJ in patients who have been 
administered bisphosphonates for longer than 3 years. 
Less than 100 pg/mL is considered high risk, 100 pg/ml 
to150 pg/mL as moderate risk, between 150 pg/mL and 
299 pg/mL as minimal risk, and greater than 300 pg/mL 
as no risk. On the other hand, Bagán et al. (4), found no 
significant relationship between this test and the number 
of exposed bone areas or the size of necrotic areas. 
A case is presented of a woman who developed ONJ af-
ter placement of dental implants. The surgery was mini-
mally invasive, carried out in a single phase and without 
complications. The guidelines of the AAOMS were fo-
llowed, removing the OB 6 months before surgery and 
applying the serum CTX test, obtaining no risk of ONJ 
(according to Marx et al. (2)). 
Case Report
The patient, a 61-year-old woman, presented to the Oral 
Surgery and Implantology Center for implant placement 
in the jaw. The patient’s medical history was positive for 
osteoporosis and she had been taking oral alendronate 
(70 mg/weekly) for 6 years and 6 months. After con-
sultation with her orthopaedic surgeon, the medication 
was removed 6 months before making the serum CTX 
test. The result was 340 pg/mL, a value that corresponds 
with “no risk of ONJ” according to Marx et al. (4) cri-
teria. Dental implants at 4.5 (series 4 of 13mm) and at 
4.7 (series 3 of 13mm) (Defcon® Avantblast, Impladent, 
Senmenat, Barcelona, Spain) were placed, following the 
guidelines of the AAOMS of 2007. Surgery was mini-
mally invasive, proceeding without incident, in a single 
phase, and placing crestal healing abutments (Fig. 1A, 
1B, 1C). Postoperative prescriptions consisted of amoxi-
cillin 500 mg and 125 mg of clavulanic acid, 1/8h, for 7 
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Fig. 1. Implant surgery in 4.5 and 4.7.A) Surgery site; B) Implant 
placement; C) Suturing; D) Ulcerated lesion lingual of 4.5 at 2 weeks 
(arrow); E) Ulcerated lesion lingual of 4.5 at 6 weeks after surgery 
(arrow); F) Complete healing at 7 months (arrow).
Fig. 2. Radiographic control. A) Radiolucent image distal of 4.5 at 2 weeks of surgery (arrow); B) Bone resorption distal of 4.5 at 7 
months (arrow); C) Maintenance of bone level at 1 year of prosthetic restoration (arrow).
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days. Two weeks later, the patients presented an asymp-
tomatic bone exposure of 1mm x 3mm, in the lingual 
area of implant 4.5 (Fig. 1D). A periapical radiography 
revealed a radiolucency distal of 4.5 (Fig. 2A). After 6 
weeks with no tissue healing (criterion established by the 
AAOMS in 2007) and no remission of the bone necrosis, 
and after dismissing other possible causes of the lesion, 
the patient was classified as stage 1 of ONJ (exposed and 
necrotic bone in asymptomatic patients without evidence 
of infection). The treatment indicated by the AAOMS in 
these patients was established: rinses (0.12%, 3 times/
day) and gel (0.2% 3 times/day) of chlorhexidine. The 
importance of maintaining good oral hygiene was em-
phasized to the patient. 
Healing improved with this treatment, decreasing the 
area of exposed bone (Fig. 1E), with neither infection 
nor pain at any time. Treatment was maintained result-
ing in complete uneventful healing of the surgical site 
at 7 months. Clinical (Fig. 1F) and radiographic exami-
nation showed bone resorption distal of 4.5 (Fig. 2B), 
disappearance of the radiolucent image suggestive of 
necrotic bone, and being bone resorption higher in this 
region (distal of the implant in 4.5) than in unaffected 
regions (mesial of the implant in 4.5; mesial and distal 
of the implant in 4.7). At 1 year, no clinical or radio-
graphic changes were observed (Fig. 2C); peri-implant 
bone level was stable. The prosthesis over implants was 
placed 3 months after healing (Fig. 3). 
implants in a patient taking OB for more than 10 years. 
Medication was not removed before surgery, treating the 
ONJ with chlorhexidine rinses 0.12% and azithromycin 
500mg/3days. In the present study, OB was removed 
6 months before placement of dental implants; healing 
was asymptomatic and an antibiotic was prescribed. 
Marx et al. (2007) (4) state that CTX values over 300pg/
mL indicate “no risk” of ONJ. The patient in the present 
study had a CTX value of 340pg/mL and still developed 
an ONJ. A study by Kunchur et al. (7), assessed the ef-
ficacy of the serum CTX test in determining the risk of 
ONJ in 348 patients taking OB; for these authors, the 
serum CTX test was not predictive in determining the 
risk of bone necrosis.
Official statements by the AAOMS in 2007 and 2009 (1) 
recommend that patients cease using OB 3 months prior 
to and 3 months after oral surgery to minimize the risk of 
ONJ. According to Marx et al. (2), if patients discontin-
ued the medication 6 months before making the analysis 
a significant improvement in CTX values is produced 
in all cases, decreasing the risk of ONJ. In the present 
study, treatment with BF ceased 6 months before the sur-
gery and still developed ONJ, being this possible due to 
the half-life of the BF in bone. 
Regarding treatment of ONJ, Marx et al. (2), state that 
if the patient has no pain, then only chlorhexidine rins-
es 0.12% should be used until complete healing of the 
ONJ. If the patient is in pain, then antibiotic therapy 
is necessary, penicillin or levofloxacin, metronidazole, 
doxycycline, and erythromycin in cases of allergy to 
penicillin. In this case report, amoxicillin/clavulanic 3 
times/day/7days was prescribed after surgery to avoid a 
possible complication. When the ONJ appeared the pa-
tient had no pain, so chlorhexidine rinses 0.12% were 
prescribed until complete healing, according to the cri-
teria of Marx et al. (2).
Ruggiero et al. (8) state that radiographic changes do not 
become evident until significant bone involvement is 
produced. Periapical radiographs may not reveal signifi-
cant changes in early stages of osteonecrosis. When ex-
tensive bone involvement is present, regions of mottled 
bone similar to that of diffuse osteomyelitis are noted 
(8). In this case report the initial periapical radiograph 
showed a radiolucent image of bone resorption, distal of 
4.5 at 2 weeks, remaining at 12 months. 
The surgery was minimally invasive, carried out in a 
single phase. There is no information in the literature 
on how to place implants in patients treated with OB; 
and this report raises the question as to whether surgery 
should be carried out in 2 phases, leaving the bone sub-
merged, in these patients. 
We believe this is the only case so far reported in the 
literature on a patient with bone necrosis in the jaw af-
ter dental implant placement, with minimally invasive, 
single phase surgery, removing oral bisphosphonates 6 
Fig. 3. Check up at 1 year of prosthetic restoration A) Occlusal view; 
B) Lateral view.
Discussion
We believe this is the first reported case of bone necro-
sis caused by OB in a patient with drug removal before 
surgery (following the guidelines of the AAOMS) and 
with no-risk serum CTX values (according to Marx et 
al.) (2).
Madrid and Sanz (5), in a systematic review, do not 
document any ONJ in patients taking OB (between 1 
and 4 years) and with dental implants. For these au-
thors, implant placement may be considered a safe pro-
cedure in patients taking OB. In contrast, Wang et al. 
(6) did present a case report of bone necrosis in dental 
e85
J Clin Exp Dent. 2012;4(1):e82-5.                         Bone necrosis, dental implants, patient with oral bisphosphonates.
months before the procedure (following AAOMS guide-
lines), and with a no risk value in the serum CTX test 
(according to Marx et al (2)). This clinical case suggests 
that further studies are needed to support the capacity of 
the serum CTX test to predict the risk of ONJ.  
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